Editorial Message and Issue Highlights – Vol. 15, No. 1 –2, January-February 2018

Dear Colleagues: Welcome to the January-February 2018 issue of Innovations in Clinical Neuroscience (ICNS). This is a milestone year for us as it marks the beginning of our 15th year of publication! We are pleased to continue serving you, our valued readers and colleagues, by providing peer-reviewed, evidence-based information on the latest innovations in both research and clinical practice in the field of neuroscience. We’d like to thank those dedicated readers who have been with us since 2004, the year we launched the journal, and to welcome new readers who are just discovering ICNS and what it has to offer. We’d also like to thank our esteemed editorial advisory board for the years of dedication and hard work they have so graciously donated to the journal. We are looking forward to seeing what exciting advances in neuroscience the next 15 years will bring us. We start this issue with a review article by Kitten et al titled, “Pimavanserin: A Novel Drug Approved to Treat Parkinson’s Disease Psychosis.” Here, the authors review the safety, efficacy, and pharmacology data for pimavanserin and its role in the treatment of psychosis in Parkinson’s disease. After conducting a literature search using MEDLINE and a reference review and search of FDA.gov and clinicaltrials.gov, the authors primarily focus on four randomized, controlled trials. The authors report that while a Phase II trial displayed a nonsignificant trend toward Scale for Assessment of Positive Symptoms ...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Editor's Message: Issue Highlights Source Type: research